Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Protection certificate |
| Status | ST | Not pending/lapsed |
21 | DE file number | DAKZ | 12 2013 000 037.6 |
| Use | VZ | Medicinal products |
95 | Product name | TIEZ | Aflibercept in Kombination mit 5-Fluorouracil |
54 | Title of basic patent | TIGZ | ANTITUMOR-KOMBINATIONEN MIT VEGF-TRAP UND 5FU ODER EINEM SEINER DERIVATE |
51 | IPC main class | ICM (ICMV) | A61K 38/17 (2006.01) |
51 | IPC secondary class(es) | ICS (ICSV) | A61K 31/505 (2006.01), A61P 35/00 (2006.01) |
94 | Start of term of protection | LB | Dec 3, 2025 |
22 | DE application date | DAT | Apr 19, 2013 |
| Date of publication of application for a certificate | OT | Jul 4, 2013 |
71/73 | Applicant/owner | INH | Aventis Pharma S.A., 20, avenue Raymond Aron, 92160 Antony, FR |
74 | Representative | VTR | ZSP Patentanwälte PartG mbB, 80686 München, DE |
| Address for service | | ZSP Patentanwälte PartG mbB, 80686 München, DE |
| Patent division in charge | | 44 |
68 | DE file number of basic patent | GAKZ | 60 2005 013 568.5 |
68 | EP file number of basic patent | GEAKZ | 05 82 4581.2 |
43 | Date of first publication | EVT | Jul 4, 2013 |
92 92 92
| Domestic authorisation | GIS GIN GIT
| Europäische Kommission EU/1/12/814/001-003 2013-02-01
|
93 93 93 93
| EU authorisation | GES GEC GEN GET
| Europäische Kommission EU EU/1/12/814/001-003 2013-02-01
|
| Date of the first transfer into DPMAregister | EREGT | Jul 4, 2013 |
| Date of the (most recent) update in DPMAregister | REGT | Aug 5, 2024 (Show all update days)(Hide all update days)- Aug 5, 2024
- St.36: changed (technical change)
- Feb 2, 2023; Dec 25, 2022; Oct 19, 2022; Jul 16, 2019; Jan 23, 2019; Sep 14, 2017; Dec 3, 2016; Jul 11, 2015; Aug 7, 2014; Jul 31, 2014; Jul 5, 2014; May 3, 2014; Mar 1, 2014; Oct 3, 2013; Sep 24, 2013; Jul 27, 2013
- Historical data not available for this/these date(s)
- Jul 4, 2013
- Date of the first transfer into DPMAregister
|